ENVERIC BIOSCI.INC.DL-01
Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the trea… Read more
Market Cap & Net Worth: ENVERIC BIOSCI.INC.DL-01 (SLZA)
ENVERIC BIOSCI.INC.DL-01 (F:SLZA) has a market capitalization of $3.32 Million (€3.24 Million) as of March 18, 2026. Listed on the F stock exchange, this Germany-based company holds position #32628 globally and #3656 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ENVERIC BIOSCI.INC.DL-01's stock price €4.67 by its total outstanding shares 692580 (692.58K).
ENVERIC BIOSCI.INC.DL-01 Market Cap History: 2019 to 2025
ENVERIC BIOSCI.INC.DL-01's market capitalization history from 2019 to 2025. Data shows change from $298.58 Million to $3.32 Million (-61.80% CAGR).
ENVERIC BIOSCI.INC.DL-01 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ENVERIC BIOSCI.INC.DL-01's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of SLZA by Market Capitalization
Companies near ENVERIC BIOSCI.INC.DL-01 in the global market cap rankings as of March 18, 2026.
Key companies related to ENVERIC BIOSCI.INC.DL-01 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
ENVERIC BIOSCI.INC.DL-01 Historical Marketcap From 2019 to 2025
Between 2019 and today, ENVERIC BIOSCI.INC.DL-01's market cap moved from $298.58 Million to $ 3.32 Million, with a yearly change of -61.80%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | €3.32 Million | +1348.84% |
| 2024 | €229.27K | -71.96% |
| 2023 | €817.55K | -25.32% |
| 2022 | €1.09 Million | -96.33% |
| 2021 | €29.86 Million | -86.00% |
| 2020 | €213.27 Million | -28.57% |
| 2019 | €298.58 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of ENVERIC BIOSCI.INC.DL-01 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.32 Million USD |
| MoneyControl | $3.32 Million USD |
| MarketWatch | $3.32 Million USD |
| marketcap.company | $3.32 Million USD |
| Reuters | $3.32 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.